Significant prostate-specific antigen (PSA) response to low-dose ketoconazole in a patient with non-metastatic androgen-independent prostate cancer (AIPC) and a review of the literature

American Journal of Therapeutics

Volumn 14, Issue 3, 2007, Pages 310-313

  Madan, Ravi A ^a   Lieberman, Ron ^b   Gulley, James L ^a   Dahut, William ^a   Arlen, Philip M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MEDIMMUNE   (United States)

Author keywords

Androgen independent prostate cancer; Androgen withdrawal; Ketoconazole

Indexed keywords

BICALUTAMIDE; CANCER VACCINE; FLUTAMIDE; GOSERELIN; KETOCONAZOLE; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ABSENCE OF SIDE EFFECTS; AGED; BLOOD ANALYSIS; CANCER SURVIVAL; CASE REPORT; DISEASE SEVERITY; DRUG WITHDRAWAL; HUMAN; LOW DRUG DOSE; MALE; MEDICAL LITERATURE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; REVIEW; TREATMENT OUTCOME;

AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KETOCONAZOLE; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 34249103844     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pap.0000249955.77460.f4     Document Type: Review

References (13)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238-244.
3. Oh WK. Secondary hormonal therapies in the treatment of prostate cancer. Urology. 2002;60:87-92.
4. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004;22:1025-1033.
5. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone ormitoxantrone plus prednisone for advanced prostate cancer. NEJM. 2004;351:1502-1512.
6. Pont A, Graybill JR, Craven PC, et al. High dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med. 1982;144:2150-2153.
7. Eichenberger T, Trachtenberg J, Toor P, et al. Ketoconazole: a possible direct cytotoxic effect on prostate carcinoma cells. J Urol. 1989;141:190-191.
8. Small EJ, Baron A, Fippin L, et al. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol. 1997;157:1204-1207.
9. Harris KA, Weinberg V, Bok RA, et al. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol. 2002;168:542-545.
10. Millikan R, Baez L, Banerjee T, et al. Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer. Urol Oncol. 2001;6:111-115.
11. Wilkinosn S, Chodak G. An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer. Eur Urol. 2004;45:581-584.
12. Scholz M, Jennrich R, Strum S, et al. Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole andhydrocortisone. J Urol. 2005;173:1947-1952.
13. Muscatto JJ, Ahmann TA, Johnson KM, et al. Optimal dosing of ketoconazole and hydrocortisone leads to long responses in hormone refractory prostate cancer [Abstract 701]. Proc Am Soc Clin Oncol. 1994:13:229.